Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures. / Madsen, Jesper J.; Ye, Libin; Frimurer, Thomas M.; Olsen, Ole H.

In: Protein Science, Vol. 31, No. 11, e4456, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Madsen, JJ, Ye, L, Frimurer, TM & Olsen, OH 2022, 'Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures', Protein Science, vol. 31, no. 11, e4456. https://doi.org/10.1002/pro.4456

APA

Madsen, J. J., Ye, L., Frimurer, T. M., & Olsen, O. H. (2022). Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures. Protein Science, 31(11), [e4456]. https://doi.org/10.1002/pro.4456

Vancouver

Madsen JJ, Ye L, Frimurer TM, Olsen OH. Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures. Protein Science. 2022;31(11). e4456. https://doi.org/10.1002/pro.4456

Author

Madsen, Jesper J. ; Ye, Libin ; Frimurer, Thomas M. ; Olsen, Ole H. / Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures. In: Protein Science. 2022 ; Vol. 31, No. 11.

Bibtex

@article{7dc6b9098c1d4de5a83a1fbfac7e8f17,
title = "Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures",
abstract = "G protein-coupled receptors (GPCRs) are important drug targets characterized by a canonical seven transmembrane (TM) helix architecture. Recent advances in X-ray crystallography and cryo-EM have resulted in a wealth of GPCR structures that have been used in drug design and formed the basis for mechanistic activation hypotheses. Here, ensemble refinement (ER) of crystallographic structures is applied to explore the impact of binding of agonists and antagonist/inverse agonists to selected structures of cannabinoid receptor 1 (CB1R), β2 adrenergic receptor (β2 AR), and A2A adenosine receptor (A2A AR). To assess the conformational flexibility and its role in GPCR activation, hydrogen bond (H-bond) networks are analyzed by calculating and comparing H-bond propensities. Mapping pairwise propensity differences between agonist- and inverse agonist/antagonist-bound structures for CB1R and β2 AR shows that agonist binding destabilizes H-bonds in the intracellular parts of TM 5-7, forming the G protein binding cavity, while H-bonds of the extracellular segment of TMs surrounding the orthosteric site are conversely stabilized. Certain class A GPCRs, for example, A2A AR, bind an allosteric sodium ion that negatively modulates agonist binding. The impact of sodium-excluding mutants (D522.50 N, S913.39 A) of A2A AR on agonist binding is examined by applying ER analysis to structures of wildtype and the two mutants in complex with a full agonist. While S913.39 A exhibits normal activity, D522.50 N quenches the downstream signaling. The mainchain H-bond pattern of the latter is stabilized in the intracellular part of TM 7 containing the NPxxY motif, indicating that an induced rigidity of the mutation prevents conformational selection of G proteins resulting in receptor inactivation.",
keywords = "allosteric regulation, ensemble refinement, G protein-coupled receptor (GPCR), hydrogen bond, molecular dynamics, protein conformation",
author = "Madsen, {Jesper J.} and Libin Ye and Frimurer, {Thomas M.} and Olsen, {Ole H.}",
note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society.",
year = "2022",
doi = "10.1002/pro.4456",
language = "English",
volume = "31",
journal = "Protein Science",
issn = "0961-8368",
publisher = "Wiley-Blackwell",
number = "11",

}

RIS

TY - JOUR

T1 - Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures

AU - Madsen, Jesper J.

AU - Ye, Libin

AU - Frimurer, Thomas M.

AU - Olsen, Ole H.

N1 - Publisher Copyright: © 2022 The Authors. Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society.

PY - 2022

Y1 - 2022

N2 - G protein-coupled receptors (GPCRs) are important drug targets characterized by a canonical seven transmembrane (TM) helix architecture. Recent advances in X-ray crystallography and cryo-EM have resulted in a wealth of GPCR structures that have been used in drug design and formed the basis for mechanistic activation hypotheses. Here, ensemble refinement (ER) of crystallographic structures is applied to explore the impact of binding of agonists and antagonist/inverse agonists to selected structures of cannabinoid receptor 1 (CB1R), β2 adrenergic receptor (β2 AR), and A2A adenosine receptor (A2A AR). To assess the conformational flexibility and its role in GPCR activation, hydrogen bond (H-bond) networks are analyzed by calculating and comparing H-bond propensities. Mapping pairwise propensity differences between agonist- and inverse agonist/antagonist-bound structures for CB1R and β2 AR shows that agonist binding destabilizes H-bonds in the intracellular parts of TM 5-7, forming the G protein binding cavity, while H-bonds of the extracellular segment of TMs surrounding the orthosteric site are conversely stabilized. Certain class A GPCRs, for example, A2A AR, bind an allosteric sodium ion that negatively modulates agonist binding. The impact of sodium-excluding mutants (D522.50 N, S913.39 A) of A2A AR on agonist binding is examined by applying ER analysis to structures of wildtype and the two mutants in complex with a full agonist. While S913.39 A exhibits normal activity, D522.50 N quenches the downstream signaling. The mainchain H-bond pattern of the latter is stabilized in the intracellular part of TM 7 containing the NPxxY motif, indicating that an induced rigidity of the mutation prevents conformational selection of G proteins resulting in receptor inactivation.

AB - G protein-coupled receptors (GPCRs) are important drug targets characterized by a canonical seven transmembrane (TM) helix architecture. Recent advances in X-ray crystallography and cryo-EM have resulted in a wealth of GPCR structures that have been used in drug design and formed the basis for mechanistic activation hypotheses. Here, ensemble refinement (ER) of crystallographic structures is applied to explore the impact of binding of agonists and antagonist/inverse agonists to selected structures of cannabinoid receptor 1 (CB1R), β2 adrenergic receptor (β2 AR), and A2A adenosine receptor (A2A AR). To assess the conformational flexibility and its role in GPCR activation, hydrogen bond (H-bond) networks are analyzed by calculating and comparing H-bond propensities. Mapping pairwise propensity differences between agonist- and inverse agonist/antagonist-bound structures for CB1R and β2 AR shows that agonist binding destabilizes H-bonds in the intracellular parts of TM 5-7, forming the G protein binding cavity, while H-bonds of the extracellular segment of TMs surrounding the orthosteric site are conversely stabilized. Certain class A GPCRs, for example, A2A AR, bind an allosteric sodium ion that negatively modulates agonist binding. The impact of sodium-excluding mutants (D522.50 N, S913.39 A) of A2A AR on agonist binding is examined by applying ER analysis to structures of wildtype and the two mutants in complex with a full agonist. While S913.39 A exhibits normal activity, D522.50 N quenches the downstream signaling. The mainchain H-bond pattern of the latter is stabilized in the intracellular part of TM 7 containing the NPxxY motif, indicating that an induced rigidity of the mutation prevents conformational selection of G proteins resulting in receptor inactivation.

KW - allosteric regulation

KW - ensemble refinement

KW - G protein-coupled receptor (GPCR)

KW - hydrogen bond

KW - molecular dynamics

KW - protein conformation

U2 - 10.1002/pro.4456

DO - 10.1002/pro.4456

M3 - Journal article

C2 - 36134696

AN - SCOPUS:85141003862

VL - 31

JO - Protein Science

JF - Protein Science

SN - 0961-8368

IS - 11

M1 - e4456

ER -

ID: 325023959